150 related articles for article (PubMed ID: 17875997)
1. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
Bogdanovich T; Clark C; Kosowska-Shick K; Dewasse B; McGhee P; Appelbaum PC
Antimicrob Agents Chemother; 2007 Nov; 51(11):4191-5. PubMed ID: 17875997
[TBL] [Abstract][Full Text] [Related]
2. In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.
Yum JH; Kim CK; Yong D; Lee K; Chong Y; Kim CM; Kim JM; Ro S; Cho JM
Antimicrob Agents Chemother; 2007 Jul; 51(7):2591-3. PubMed ID: 17420210
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Jørgen B; Merckoll P; Melby KK
Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
[TBL] [Abstract][Full Text] [Related]
5. Resistance selection studies comparing the activity of razupenem (PTZ601) to vancomycin and linezolid against eight methicillin-resistant and two methicillin-susceptible Staphylococcus aureus strains.
Clark C; Kosowska-Shick K; McGhee P; Dewasse B; Beachel L; Appelbaum PC
Antimicrob Agents Chemother; 2009 Jul; 53(7):3118-21. PubMed ID: 19433566
[TBL] [Abstract][Full Text] [Related]
6. Antistaphylococcal activities of CG400549, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor.
Park HS; Yoon YM; Jung SJ; Kim CM; Kim JM; Kwak JH
J Antimicrob Chemother; 2007 Sep; 60(3):568-74. PubMed ID: 17606482
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
Leuthner KD; Vidaillac C; Cheung CM; Rybak MJ
Antimicrob Agents Chemother; 2010 Sep; 54(9):3799-803. PubMed ID: 20585126
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Mendes RE; Moet GJ; Janechek MJ; Jones RN
Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
[TBL] [Abstract][Full Text] [Related]
9. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound.
Escaich S; Prouvensier L; Saccomani M; Durant L; Oxoby M; Gerusz V; Moreau F; Vongsouthi V; Maher K; Morrissey I; Soulama-Mouze C
Antimicrob Agents Chemother; 2011 Oct; 55(10):4692-7. PubMed ID: 21825292
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Cha R; Brown WJ; Rybak MJ
Antimicrob Agents Chemother; 2003 Dec; 47(12):3960-3. PubMed ID: 14638509
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
12. In vitro bactericidal activity of daptomycin against staphylococci.
Fuchs PC; Barry AL; Brown SD
J Antimicrob Chemother; 2002 Mar; 49(3):467-70. PubMed ID: 11864946
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
[TBL] [Abstract][Full Text] [Related]
14. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
15. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
Kosowska-Shick K; Clark C; Pankuch GA; McGhee P; Dewasse B; Beachel L; Appelbaum PC
Antimicrob Agents Chemother; 2009 Oct; 53(10):4217-24. PubMed ID: 19620338
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.
Rybak MJ; Hershberger E; Moldovan T; Grucz RG
Antimicrob Agents Chemother; 2000 Apr; 44(4):1062-6. PubMed ID: 10722513
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
Antimicrob Agents Chemother; 2003 Jan; 47(1):337-41. PubMed ID: 12499210
[TBL] [Abstract][Full Text] [Related]
18. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus.
Muñoz Bellido JL; Gutiérrez Zufiaurre MN; Sánchez Hernández FJ; Yagüe Guirao G; Segovia Hernández M; García-Rodríguez JA
Int J Antimicrob Agents; 2002 Jul; 20(1):61-4. PubMed ID: 12127713
[TBL] [Abstract][Full Text] [Related]
20. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]